Crigler-Najjar Syndrome Market Insights 2019-2026: Audentes Therapeutics, Genethon SA, International Stem Cell Corp

Crigler-Najjar Syndrome Market

This Crigler-Najjar Syndrome report offers the Port’s five force analysis which is a powerful tool for understanding the competitiveness of  your business environment and identifying  your  strategy’s potential profitability. It analyzes the competitive rivalry which give information about the competitors in the market and their strategies to strive in the business. This Crigler-Najjar Syndrome report provides information of threat of new entrants, supplier power, competitive rivalry and threat of substitution. Growth including factors, market restraints and  recent developments have also been analyzed in the report in order to provide deeper knowledge about the industry.

Crigler–Najjar syndrome is rare genetic liver disorder characterized by abnormal accumulation of bilirubin, a yellow pigment produced by the liver. This accumulation is caused by deficiency of the enzyme called UGT1A1. This enzyme is responsible for the conversion of bilirubin into a substance that can be eliminated. Crigler–Najjar Syndrome can cause significant neurological damage.

Key Market Players: International Stem Cell Corporation, Promethera, Selecta Biosciences, Inc, LOGICBIO THERAPEUTICS, INC, Genethon, Audentes Therapeutics, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Endo Pharmaceuticals Inc, ANI Pharmaceuticals, Inc, Mylan N.V., Glenmark Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC, Epic Pharma, LLC, Lannett and others

Request for Sample Report @

Crigler-Najjar Syndrome market research report has been formulated by using basic steps to conduct market research analysis which includes survey, focus groups, personal interviews, observations and field trials. This Crigler-Najjar Syndrome market report cover strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. The report provides an all-inclusive study on production capacity, consumption, import and export for all major regions across the globe. With the use of excellent resources and latest tools, this best in class Crigler-Najjar Syndrome market research report has been created to aid your business growth.

According to the statistics published in the U.S. Department of Health & Human Services, an estimated annual prevalence of Crigler-Najjar syndrome is 1 in one million newborns worldwide. Increasing research and development expenses and high demand of novel therapies are some factors fueling the market growth.

Global Crigler–Najjar Syndrome Market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Presence of refined healthcare infrastructure and increase in special designation from the regulatory authorities are the key factors that drive the market.

Market Drivers

  • Huge financial support to the researchers for developing novel intervention is boosting the market growth
  • Increase in demand of disease specific novel treatment can also act as a market driver
  • Family history of Crigler–Najjar syndrome is driving the growth of the market
  • Increase in special designation from the regulatory authorities is drive the market

Segmentation: Global Crigler–Najjar Syndrome Market

By Treatment

  • Medication
  • Surgery

By Drugs

  • Bilirubin Chelators
  • Ursodeoxycholic Acid
  • Others

By Route of Administration

  • Oral
  • Injectable

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Key Developments in the Market:

  • In February 2018, Audentes Therapeutics has initiated a first dose of patients in VALENS, a Phase I/II clinical trial of AT342, a gene therapy for the treatment of Crigler-Najjar Syndrome. AT342 has received Rare Pediatric Disease and Fast Track designations from the FDA. These designations provide significant benefits to the company including opportunities to work with the FDA to expedite the development of AT342.
  • In December 2018, Genethon initiated the dosing of patients in phase I/II trial (CareCN) of novel gene therapy for the treatment of Crigler–Najjar Syndrome. If trial successful, it could be first approved drug for treatment of patient suffering from this devastating disease.

Browse Full Report with Details TOC @

Competitive Analysis:

Global Crigler–Najjar syndrome market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global Crigler–Najjar syndrome market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

There are 15 Chapters to display the Global Crigler-Najjar Syndrome Drug market

Chapter 1, Definition, Specifications and Classification of Crigler-Najjar Syndrome Drug , Applications of Crigler-Najjar Syndrome Drug , Market Segment by Regions;
Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;
Chapter 3, Technical Data and Manufacturing Plants Analysis of Crigler-Najjar Syndrome Drug , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;
Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);
Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Crigler-Najjar Syndrome Drug Segment Market Analysis (by Type);
Chapter 7 and 8, The Crigler-Najjar Syndrome Drug Segment Market Analysis (by Application) Major Manufacturers Analysis of Crigler-Najjar Syndrome Drug ;
Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type ALXN-1540, AT-342, HepaStem, Others, Market Trend by Application Hospital, Clinic, Others;
Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;
Chapter 11, The Consumers Analysis of Global Crigler-Najjar Syndrome Drug ;
Chapter 12, Crigler-Najjar Syndrome Drug Research Findings and Conclusion, Appendix, methodology and data source;
Chapter 13, 14 and 15, Crigler-Najjar Syndrome Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Inquiry before Buying @

Research Methodology: Global Crigler–Najjar Syndrome Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons for Buying Crigler-Najjar Syndrome Drug market

This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth
It provides a six-year forecast assessed on the basis of how the market is predicted to grow
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

About Data Bridge Market Research:        

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

Report Rating